Literature DB >> 19416364

Bacteriophage and their lysins for elimination of infectious bacteria.

Sarah O'Flaherty1, R Paul Ross, Aidan Coffey.   

Abstract

When phages were originally identified, the possibility of using them as antibacterial agents against pathogens was immediately recognized and put into practise based on the knowledge available at the time. However, with the advent of antibiotics a decline in the use of phage as therapeutics followed. Phages did, however, become more useful in the study of fundamental aspects of molecular biology and in the diagnostic laboratory for the identification of pathogenic bacteria. More recently, the original application of phage as therapeutics to treat human and animal infections has been rekindled, particularly in an era where antibiotic resistance has become so problematic/commonplace. Phage lysins have also been studied and utilized in their own right as potential therapeutics for the treatment of bacterial infections. Indeed the past decade has seen a considerable amount of research worldwide focused on the engineering of phages as antibacterial agents in a wide range of applications. Furthermore, the US Food and Drug Administration and/or the US Department of Agriculture have recently approved commercial phage preparations to prevent bacterial contamination of livestock, food crops, meat and other foods. Such developments have prompted this review into the status of phage research as it pertains to the control of infectious bacteria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416364     DOI: 10.1111/j.1574-6976.2009.00176.x

Source DB:  PubMed          Journal:  FEMS Microbiol Rev        ISSN: 0168-6445            Impact factor:   16.408


  73 in total

1.  P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.

Authors:  Ragini Gupta; Yogendra Prasad
Journal:  Curr Microbiol       Date:  2011-04-27       Impact factor: 2.188

Review 2.  Bacteriophage resistance mechanisms.

Authors:  Simon J Labrie; Julie E Samson; Sylvain Moineau
Journal:  Nat Rev Microbiol       Date:  2010-03-29       Impact factor: 60.633

3.  Characterization of lytic enzyme open reading frame 9 (ORF9) derived from Enterococcus faecalis bacteriophage phiEF24C.

Authors:  Jumpei Uchiyama; Iyo Takemura; Ikue Hayashi; Shigenobu Matsuzaki; Miho Satoh; Takako Ujihara; Masanao Murakami; Masayuki Imajoh; Motoyuki Sugai; Masanori Daibata
Journal:  Appl Environ Microbiol       Date:  2010-11-19       Impact factor: 4.792

4.  Molecular dissection of phage lysin PlySs2: integrity of the catalytic and cell wall binding domains is essential for its broad lytic activity.

Authors:  Yanling Huang; Hang Yang; Junping Yu; Hongping Wei
Journal:  Virol Sin       Date:  2015-02-04       Impact factor: 4.327

5.  Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 HydH5 virion-associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5.

Authors:  Lorena Rodríguez-Rubio; Beatriz Martínez; Ana Rodríguez; David M Donovan; Pilar García
Journal:  Appl Environ Microbiol       Date:  2012-01-20       Impact factor: 4.792

6.  Biosafety evaluation of bacteriophages for treatment of diarrhea due to intestinal pathogen Escherichia coli 3-2 infection of chickens.

Authors:  Hao Li; Man-Li Ma; Hui-Jun Xie; Jian Kong
Journal:  World J Microbiol Biotechnol       Date:  2011-05-15       Impact factor: 3.312

Review 7.  Mycoviruses: future therapeutic agents of invasive fungal infections in humans?

Authors:  W W J van de Sande; J R Lo-Ten-Foe; A van Belkum; M G Netea; B J Kullberg; A G Vonk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-02       Impact factor: 3.267

8.  Different approaches for using bacteriophages against antibiotic-resistant bacteria.

Authors:  Ido Yosef; Ruth Kiro; Shahar Molshanski-Mor; Rotem Edgar; Udi Qimron
Journal:  Bacteriophage       Date:  2014-03-11

Review 9.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

10.  Minimal requirements for inhibition of MraY by lysis protein E from bacteriophage ΦX174.

Authors:  Shiho Tanaka; William M Clemons
Journal:  Mol Microbiol       Date:  2012-07-13       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.